Although psoriatic arthritis may be more prevalent in White patients, Rebecca Haberman, MD, of NYU Langone Health, emphasizes that the disease affects those across diverse racial and ethnic backgrounds.
In part 1 of an interview with The American Journal of Managed Care®, Rebecca Haberman, MD, rheumatologist and associate director of the Psoriatic Arthritis Center at NYU Langone Health, discusses how the historical perception of psoriatic arthritis (PsA) as a "Caucasian" disease has shaped clinical understanding and research efforts. She also shares what inspired her to explore racial and ethnic differences among patients with PsA in a recent study.
This transcript has been lightly edited for clarity.
Transcript
Given that PsA was historically considered a "Caucasian" disease, how has that perception influenced clinical understanding and research efforts?
A lot of times, people are thinking of psoriasis and PsA as White diseases. So, a lot of times, people who are non-White get kind of ignored or put almost on the back burner. First of all, clinically, psoriasis doesn't look the same on all skin tones. So, a lot of times psoriasis in itself can be undiagnosed or even misdiagnosed. Then, once they don't have psoriasis, the first thing that comes to mind for rheumatologists is not necessarily PsA.
When you look at studies, especially clinical trials, they're often over 90%, sometimes over 95%, White. This doesn't reflect accurately the prevalence of the disease, as is seen in nationwide studies or surveys. Dr April Armstrong had done a study looking at the NHANES [National Health and Nutrition Examination Survey] survey data and found that the prevalence of psoriasis, so skin psoriasis, is 3.6% in White individuals but also 2.5% in Asian individuals, 1.9% in Hispanic individuals, and 1.5% in Black individuals.
The same sort of breakdown in pattern is seen in PsA. So, even though, yes, the prevalence might be higher, it's certainly not everyone who has this disease. So, we've really been almost neglecting a little bit the other parts of this disease.
What motivated you to investigate racial and ethnic differences in PsA? What gaps in the literature were you hoping to address?
So, there isn't that much research out there actually looking at this. A lot of the studies that are out there focus on skin psoriasis, in particular. But looking at PsA, there are maybe 2, maybe 3 studies that were already out there. What we found is we're here in New York, we have a very large urban center that includes a private network and a public hospital. Just being in New York, there's a lot of different diversity here.
What we realized is that the patients that we were seeing in our private practices at Bellevue Hospital looked different than a lot of these studies that we were seeing in the literature, that we had a very unique population that was ethnically diverse, racially diverse, socioeconomically diverse, just a ton of diversity there. So, we found ourselves in a really unique position to look at this. So, we decided that we really wanted to focus on how our population can contribute largely to the PsA research throughout the country and throughout the world.
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Sugammadex Safe, Effective Post Surgery in Myasthenia Gravis
February 18th 2025Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular blockade from rocuronium bromide or vecuronium bromide.
Read More